Reviewing the regulatory barriers for nanomedicine

Global questions and challenges

Diana Bowman, Jake Gatof

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nanomedicine will play an increasing role in prevention and treatment across the entire healthcare spectrum. However, their precise market size, economic value and areas of application remain unclear. This opacity, including the question of what constitutes nanomedicine matters, especially when considered alongside the key regulatory questions and concerns. This article begins by placing these key questions into context in relation to the current scientific state of the art, focusing particular attention on the human health and safety context. In exploring these central questions surrounding the regulation of nanomedicine, this perspective also explores existing and suggested frameworks that aim to deal with emerging technologies more generally. It then outlines priority areas for action and general conclusions specific to nanomedicine.

Original languageEnglish (US)
Pages (from-to)3275-3286
Number of pages12
JournalNanomedicine
Volume10
Issue number21
DOIs
StatePublished - Nov 1 2015

Fingerprint

Nanomedicine
Medical nanotechnology
economic area
economic value
health and safety
health care
regulation
market
health
economics
Opacity
Economics
Health
Technology
Delivery of Health Care
Safety
state of the art
human health

Keywords

  • EU
  • global challenges
  • governance
  • health and safety
  • innovation
  • intellectual property
  • nanomaterials
  • regulation
  • USA

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Reviewing the regulatory barriers for nanomedicine : Global questions and challenges. / Bowman, Diana; Gatof, Jake.

In: Nanomedicine, Vol. 10, No. 21, 01.11.2015, p. 3275-3286.

Research output: Contribution to journalArticle

@article{cef00a41c7674cbc9af45e5f0375f60e,
title = "Reviewing the regulatory barriers for nanomedicine: Global questions and challenges",
abstract = "Nanomedicine will play an increasing role in prevention and treatment across the entire healthcare spectrum. However, their precise market size, economic value and areas of application remain unclear. This opacity, including the question of what constitutes nanomedicine matters, especially when considered alongside the key regulatory questions and concerns. This article begins by placing these key questions into context in relation to the current scientific state of the art, focusing particular attention on the human health and safety context. In exploring these central questions surrounding the regulation of nanomedicine, this perspective also explores existing and suggested frameworks that aim to deal with emerging technologies more generally. It then outlines priority areas for action and general conclusions specific to nanomedicine.",
keywords = "EU, global challenges, governance, health and safety, innovation, intellectual property, nanomaterials, regulation, USA",
author = "Diana Bowman and Jake Gatof",
year = "2015",
month = "11",
day = "1",
doi = "10.2217/nnm.15.169",
language = "English (US)",
volume = "10",
pages = "3275--3286",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "21",

}

TY - JOUR

T1 - Reviewing the regulatory barriers for nanomedicine

T2 - Global questions and challenges

AU - Bowman, Diana

AU - Gatof, Jake

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Nanomedicine will play an increasing role in prevention and treatment across the entire healthcare spectrum. However, their precise market size, economic value and areas of application remain unclear. This opacity, including the question of what constitutes nanomedicine matters, especially when considered alongside the key regulatory questions and concerns. This article begins by placing these key questions into context in relation to the current scientific state of the art, focusing particular attention on the human health and safety context. In exploring these central questions surrounding the regulation of nanomedicine, this perspective also explores existing and suggested frameworks that aim to deal with emerging technologies more generally. It then outlines priority areas for action and general conclusions specific to nanomedicine.

AB - Nanomedicine will play an increasing role in prevention and treatment across the entire healthcare spectrum. However, their precise market size, economic value and areas of application remain unclear. This opacity, including the question of what constitutes nanomedicine matters, especially when considered alongside the key regulatory questions and concerns. This article begins by placing these key questions into context in relation to the current scientific state of the art, focusing particular attention on the human health and safety context. In exploring these central questions surrounding the regulation of nanomedicine, this perspective also explores existing and suggested frameworks that aim to deal with emerging technologies more generally. It then outlines priority areas for action and general conclusions specific to nanomedicine.

KW - EU

KW - global challenges

KW - governance

KW - health and safety

KW - innovation

KW - intellectual property

KW - nanomaterials

KW - regulation

KW - USA

UR - http://www.scopus.com/inward/record.url?scp=84944939648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944939648&partnerID=8YFLogxK

U2 - 10.2217/nnm.15.169

DO - 10.2217/nnm.15.169

M3 - Article

VL - 10

SP - 3275

EP - 3286

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 21

ER -